Sometimes during the lifetime of a company significant shifts in priorities and resource allocation are made. I believe the ability to recognize the need for such changes and the wherewithal to carry … [Read more...] about DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
One of the most heralded oncology conferences is the annual American Society of Clinical Oncologists (ASCO). This year, Chicago is hosting the annual conference, which is running from May 31st through … [Read more...] about ASCO Alert: Stay Ahead of the Updates
Leave a comment and click here to sub for MS article alerts and our newsletter! Overview January 14th, the FDA approved cabozantinib (CABOMETYX) for the treatment of hepatocellular carcinoma (HCC) in … [Read more...] about FDA Approves Cabozantinib; But it’s Not Alone
Leave a comment and click here to subscribe for MS article alerts and our newsletter! MRK Exercises Option For NGM Bio's Investigational Insulin Sensitizer-NGM313 January 3rd, 2019 MRK … [Read more...] about MS Morning Update
GALT’s phase 3 study inclusion criteria will be patients diagnosed with NASH-cirrhosis but without varices, and includes an interim analysis. Competition in the NASH-cirrhosis space is lacking. The … [Read more...] about Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership